Tickers
Zoetis (ZTS) shares rose after the company beat third-quarter earnings and revenue estimates and improved its 2026 profit outlook, though organic operational revenue fell 1% in the quarter. Global livestock revenue rose 7% to $797 million, partially offsetting weakness in companion-animal products, which still account for most of Zoetis’s revenue (about 30% comes from livestock healthcare). The results mark a rebound from the stock’s earlier decline, when a cautious 2027 outlook signaled softer demand as pet owners cut back on veterinary visits. A Seeking Alpha analysis published November 6, 2026, argued the stock is a quality compa…
Zoetis Shares Rise After Q3 Beat and Improved 2026 Profit Outlook
Zoetis (ZTS) shares rose after the animal-health company beat third-quarter earnings and revenue estimates and improved its 2026 profit outlook, according to an editorial summary of the results.
The quarter was not uniformly strong. Organic operational revenue fell 1%, the summary said.
Segment Performance
- Global livestock revenue rose 7% to $797 million, partially offsetting weakness in companion-animal products.
- Companion-animal products still account for most of Zoetis’s revenue, with approximately 30% coming from livestock healthcare solutions, according to a Seeking Alpha analysis published November 6, 2026.
Background on the Stock
The results mark a rebound from the stock’s earlier decline, when a cautious 2027 outlook signaled softer demand as pet owners cut back on veterinary visits, the summary said.
Company Profile
Zoetis Inc., formerly Pfizer’s veterinary arm, is described in the Seeking Alpha analysis as a global leader in animal pharmaceuticals and diagnostics. The analysis states that the stock “has done so poorly” and outlines the author’s case for a long position, framing Zoetis as a quality company trading cheap.